Breaking News

WuXi API Facility Passes FDA Inspection

August 18, 2014

To manufacture API for branded commercial drug

WuXiPharmaTech’s subsidiary, Shanghai SynTheAll Pharmaceutical Co. Ltd. (STA), passed an FDA inspection in July for the manufacture of the API for an undisclosed branded commercial drug.
 
This is the first FDA inspection of STA's facilities for the manufacture of an API. The company had previously received FDA approval for the manufacture of an advanced intermediate. STA provides process research to commercial manufacturing.
 
"We are very pleased to have passed a second FDA inspection of our manufacturing facilities," said Dr. Ge Li, chairman and chief executive officer of WuXiPharmaTech. "These favorable outcomes reflect our dedication to maintaining the highest quality standards throughout our organization."
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision